Breast Cancer Research, 2023 Background Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of the patients respond to it completely.
Witali Aswolinskiy +15 more
doaj +1 more source
Monitoring Breast Cancer Response to Neoadjuvant Chemotherapy Using Ultrasound Strain Elastography [PDF]
, 2019 © 2019 The Authors Strain elastography was used to monitor response to neoadjuvant chemotherapy (NAC) in 92 patients with biopsy-proven, locally advanced breast cancer. Strain elastography data were collected before, during, and after NAC.
Curpen, B. +12 more
core +1 more source
Namık Kemal Tıp Dergisi, 2021 Aim:In our study, we aimed to determine the clinicopathological factors affecting the pathological response after neoadjuvant chemotherapy in HER2 positive breast cancer.Materials and Methods:A total of 54 HER2 expression positive cases were included in ...
Abdullah Evren YETİŞİR, Semra PAYDAŞ
doaj +1 more source
Magnetic resonance tumor regression grade (MR-TRG) to assess pathological complete response following neoadjuvant radiochemotherapy in locally advanced rectal cancer [PDF]
, 2017 This study aims to evaluate the feasibility of a magnetic resonance (MR) automatic method for quantitative assessment of the percentage of fibrosis developed within locally advanced rectal cancers (LARC) after neoadjuvant radiochemotherapy (RCT). A total
Bellini, D +10 more
core +1 more source
HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer [PDF]
, 2014 Background: HAGE protein is a known immunogenic cancer-specific antigen. Methods: The biological, prognostic and predictive values of HAGE expression was studied using immunohistochemistry in three cohorts of patients with BC (n=2147): early primary (EP ...
A G Pockley +48 more
core +3 more sources
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? [PDF]
, 2015 BACKGROUND: Neoadjuvant breast cancer trials are important for speeding up the introduction of new treatments for patients with early breast cancer and for the highly productive translational research which they facilitate.
Abraham, Jean +6 more
core +3 more sources
Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer [PDF]
, 2019 Background: In patients who have had axillary nodal metastasis diagnosed prior to neoadjuvant chemotherapy for breast cancer, there is little consensus on how to manage the axilla subsequently.
A Gangi +35 more
core +2 more sources
Chronic thoracic hemisection spinal cord injury in adult rats induces a progressive decline in transmission from uninjured fibers to lumbar motoneurons [PDF]
, 2008 Although most spinal cord injuries are anatomically incomplete, only limited functional recovery has been observed in people and rats with partial lesions.
Arko Ghosh +10 more
core +2 more sources
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study [PDF]
, 2019 Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple
Apolone G. +18 more
core +2 more sources
Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer [PDF]
, 2005 Background: Induct ion chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials.
BORDONARO R. +10 more
core +1 more source